Clinical Study Of Hepatic Arterial Infusion Chemotherapy Combined With Anti-PD-1 Antibody And Lenvatinib In The Treatment Of Unresectable Hepatocellular Carcinoma

Objective:To explore the efficacy and safety of improved FOLFOX6 regimen for hepatic artery infusion chemotherapy combined with anti-PD-1 antibody and lenvatinib in the treatment of unresectable hepatocellular carcinomaMethods: Patients with primary hepatocellular carcinoma diagnosed by pathological biopsy or clinical diagnosis from May 2020 to January2022 received HAIC therapy with m FOLFOX6 regimen(21d/time),along with immunotherapy against programmed death receptor-1antibodies(200mg 21d/time),and targeted therapy with lenvatinib(<60kg:8mg/d;≧60kg:12mg/d)until the efficacy evaluation is CR(m RECIST1.1 standard)or the indication for translational therapy is met,or the adverse reactions of liver function Child Pugh C grade and intolerable adverse reactions occur.Observe the adverse reactions caused by the treatment process,follow up and review regularly,and evaluate the efficacy of tumor reatment.Results: The average age of the patients in the included group was55.3±12.2 years old,males accounted for the vast majority(85.7%),accompanied by chronic hepatitis B accounted for 87.3%,in line with the characteristics of hepatocellular carcinoma in China;All patients were inoperable to remove hepatocellular carcinoma,of which 54.0% were invaded by large vessels,the maximum diameter of tumor target lesions was greater than 5cm,accounting for 68.3%,and the background of cirrhosis was obvious(92.1%),the tumor stage was late,the burden was heavy,and the tumor response: 6 months PFS was 68.9%,The m PFS was10.20 months(95% CI: 6.34-14.06),the median follow-up was 6.9months(1.4 to 21.0 months),m OS was 17 months(95% CI: 11.58-22.42),and the cumulative 1-year OS was 62.5%.Safety of treatment: no patients developed catheterization-related complications during the course of treatment,and no patients developed intolerable adverse reactions.Conclusion:The combination of m FOLFOX6-HAIC combined with anti-PD-1 antibody and lenvatinib treatment of unresectable hepatocellular carcinoma can achieve CR,and tumor treatment is well reactive,the surgical conversion rate is high,and the adverse reactions in the treatment process are also controllable.